- Migraine biotech Vedana Therapeutics makes its debut with $46M Series AVedana Therapeutics has emerged from stealth with $46 million in Series A proceeds with the goal of developing treatments that could free patients from migraines entirely. Available treatments for…Endpoints · 1mo ago↗ source
- A new Westlake-backed biotech takes aim at migrainesVedana Therapeutics emerged from stealth Wednesday with $46 million to support its mission of developing “anti-PACAP” therapies, an increasingly popular strategy for migraine prevention.BioPharma Dive · 1mo ago↗ source
- Health groups say HHS is trying to 'rush reinstatement' of ACIPA group of health organizations has accused HHS of trying to use a “self-created crisis” to “rush reinstatement” of the CDC’s frozen vaccine advisory panel. The committee and its recommendations ar…